ライフサイエンスコーパス: solid organ transplantation

1 s, but also as an unavoidable consequence of solid organ transplantation.

2 future is improving long-term outcomes after solid organ transplantation.

3 used to prevent rejection and graft loss in solid organ transplantation.

4 -mediated rejection and graft loss after all solid organ transplantation.

5 ty (APA) is recommended in patients awaiting solid organ transplantation.

6 challenge limiting allograft survival after solid organ transplantation.

7 volved in myocardial infarction, stroke, and solid organ transplantation.

8 The incidence of cancer is increased after solid organ transplantation.

9 y a significant role in graft survival after solid organ transplantation.

10 k of cytomegalovirus (CMV) replication after solid organ transplantation.

11 is an infrequent but serious complication of solid organ transplantation.

12 lograft survival is a major challenge facing solid organ transplantation.

13 ve drugs is one of the key research goals in solid organ transplantation.

14 f peanut allergy has been reported following solid organ transplantation.

15 of hematopoiesis and to induce tolerance for solid organ transplantation.

16 munocompromised patients, particularly after solid organ transplantation.

17 (HHV) and immune control of replication post-solid organ transplantation.

18 neity of lymphatic vessels in the context of solid organ transplantation.

19 geographic variation in CMV management after solid organ transplantation.

20 nsplantation monitoring of HLA antibodies in solid organ transplantation.

21 major cause of mortality and morbidity after solid organ transplantation.

22 ettings, it has received little attention in solid organ transplantation.

23 limus may also be associated with PRES after solid organ transplantation.

24 SC) transplantation, autoimmune disease, and solid organ transplantation.

25 een made in improving short-term outcomes in solid organ transplantation.

26 V) is a common opportunistic infection after solid organ transplantation.

27 mon, but challenging type of rejection after solid organ transplantation.

28 rs, and outcomes of colectomy for CDAD after solid organ transplantation.

29 Corneal transplantation is the most common solid organ transplantation.

30 es may improve chronic CNI nephrotoxicity in solid organ transplantation.

31 ) is one of the most common infections after solid organ transplantation.

32 intravenous drug use, radiation therapy, and solid organ transplantation.

33 ively ameliorates the consequences of IRI in solid organ transplantation.

34 al trials as a potential therapy in cell and solid organ transplantation.

35 iants that seem to impact outcomes following solid organ transplantation.

36 unosuppression minimization or withdrawal in solid organ transplantation.

37 utcome of rare PTLD subtypes in adults after solid organ transplantation.

38 ) closely follows the standard practices for solid organ transplantation.

39 to delay or prevent chronic rejection after solid organ transplantation.

40 e, is a highly desirable therapeutic goal in solid organ transplantation.

41 HL is a late complication of solid organ transplantation.

42 an exceptional finding after other types of solid organ transplantation.

43 mmunosuppressed patients, particularly after solid organ transplantation.

44 nifest different complications compared with solid organ transplantation.

45 Allograft rejection remains the nemesis of solid organ transplantation.

46 been associated with allograft rejection in solid organ transplantation.

47 cer is an increasing and major problem after solid organ transplantation.

48 or improved control of viral hepatitis after solid organ transplantation.

49 target this intractable problem in clinical solid organ transplantation.

50 l antibody increasingly used at induction in solid organ transplantation.

51 e smaller than other hazards associated with solid organ transplantation.

52 the context of the two most common forms of solid organ transplantation.

53 uzumab has been used in off-label studies of solid organ transplantation.

54 n diagnosis and personalized therapeutics in solid organ transplantation.

55 erm follow-up to determine its exact role in solid organ transplantation.

56 disorder (PTLD) is a serious complication of solid organ transplantation.

57 kidney dysfunction in recipients of nonrenal solid organ transplantation.

58 system participate in the immune response to solid organ transplantation.

59 ch using MRI to detect graft rejection after solid organ transplantation.

60 established as an immunosuppressive agent in solid organ transplantation.

61 omplication after hematopoietic stem cell or solid organ transplantation.

62 lograft survival in several animal models of solid organ transplantation.

63 es mellitus (PTDM) is a common problem after solid organ transplantation.

64 s published in the last 12 months in HIV and solid organ transplantation.

65 as efficacious and safe through their use in solid organ transplantation.

66 ng the sphingosine 1-phosphate receptor 1 in solid organ transplantation.

67 of novel immunosuppressive drugs for use in solid organ transplantation.

68 define the role of MP therapeutic agents in solid organ transplantation.

69 circulation is an early marker of injury in solid organ transplantation.

70 hing is a risk factor for graft rejection in solid organ transplantation.

71 including stroke, myocardial infarction, and solid organ transplantation.

72 eed for systemic immunosuppression in VCA or solid organ transplantation.

73 ening and vaccination of all patients before solid organ transplantation.

74 ative correlation with long-term survival in solid organ transplantation.

75 nition of being physically active) following solid organ transplantation.

76 thogenesis of ischemia-reperfusion injury in solid organ transplantation.

77 ary Epstein-Barr virus (EBV) infection after solid organ transplantation.

78 hematopoietic stem cell transplantation and solid organ transplantation.

79 he development of immunoregulation following solid organ transplantation.

80 Diarrhea is a frequent complication of solid organ transplantation.

81 oles in the cellular and humoral response in solid organ transplantation.

82 dressing the organ supply/demand mismatch in solid organ transplantation.

83 cluding those associated with bone marrow or solid organ transplantation.

84 ications of this novel MPS classification in solid organ transplantation.

85 s and outcomes associated with smoking after solid organ transplantation.

86 us 8 (HHV-8)-related disease described after solid organ transplantation.

87 l as after allogeneic hematopoietic cell and solid organ transplantation.

88 allograft loss in most (if not all) types of solid-organ transplantation.

89 lcohol and substance abuse in the context of solid-organ transplantation.

90 TLD) is a well-recognized complication after solid-organ transplantation.

91 e disorder (PTLD) is a major complication of solid-organ transplantation.

92 eating pediatric with EBV (+) PTLD following solid-organ transplantation.

93 tion of a new arenavirus transmitted through solid-organ transplantation.

94 (3) children with hematopoietic stem cell or solid-organ transplantation.

95 ingle most important long-term limitation to solid-organ transplantation.

96 CKD) is a common complication after nonrenal solid-organ transplantation.

97 unization can present a special challenge to solid-organ transplantation.

98 not been thoroughly investigated in nonrenal solid-organ transplantation.

99 t transfusion support of patients undergoing solid-organ transplantation.

100 on systems have successfully been applied in solid organ transplantations.

101 er lung transplantation are the lowest among solid organ transplantations.

102 ately 50%, which is far behind that of other solid organ transplantations.

103 o not always mimic those of the well-studied solid organ transplantations.

104 with prior coccidioidomycosis who underwent solid organ transplantation (18 liver, 24 kidney, 3 panc

105 Major underlying diseases were solid organ transplantation (24%), diabetes mellitus (22

106 Of 13 318 eligible survivors, 100 had 103 solid organ transplantations (50 kidney, 37 heart, nine

107 er-related factors (hospital with <800 beds, solid organ transplantation activity, higher annual inci

108 As a complication of solid organ transplantation, acute graft-versus-host dis

109 ere neutropenia, hematopoietic stem cell and solid organ transplantation, advanced AIDS, and chronic

110 Pregnancy after solid organ transplantation, although considered high ri

111 International travel was common after solid organ transplantation, although the majority trave

112 tration on a waiting list for or receiving a solid organ transplantation and 5-year survival followin

113 ause of a complex diagnosis especially after solid organ transplantation and can lead to difficulties

114 ent a meta-analysis of clinical trials after solid organ transplantation and describe potential mecha

115 nchymal stem cells as a therapeutic agent in solid organ transplantation and emphasizes the issues (p

116 are similar to those usually reported after solid organ transplantation and have prompted different

117 ient mixed hematopoietic chimerism (MC) when solid organ transplantation and HCT are done concomitant

118 nes on the prevention and treatment of TB in solid organ transplantation and hematopoietic stem cell

119 Belying the spectacular success of solid organ transplantation and improvements in immunosu

120 injury (IRI) is an unavoidable event during solid organ transplantation and is a major contributor t

121 ociated with rejection and allograft loss in solid organ transplantation and may act synergistically

122 g the periocular region represents a risk of solid organ transplantation and may produce significant

123 mpatibility between patient and donor before solid organ transplantation and preventing hyperacute re

124 8 patients were identified who had undergone solid organ transplantation and subsequently underwent c

125 description of a pathogenic role for NETs in solid organ transplantation and suggest that NETs are a

126 he basis for future clinical applications of solid organ transplantation and that T-regulatory cells

127 ood and Drug Administration to be used after solid organ transplantation and to treat pemphigus vulga

128 The largest reductions in solid organ transplantation and waitlist deaths were see

129 ms are used to prolong allograft survival in solid organ transplantations and have been shown to be s

130 abuse are common and may lead to a need for solid-organ transplantation and may also contribute to s

131 arity to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of

132 cute and chronic rejection in the context of solid organ transplantation, and emerging evidence sugge

133 currently being realised in animal models of solid organ transplantation, and offers great hope for c

134 most prevalent infectious complication after solid organ transplantation, and recipients of isolated

135 of childbearing age, toddlers, recipients of solid organ transplantation, and stem cell transplant pa

136 Cancer incidence is different among solid organ transplantations, and ratios may be higher t

137 deed required in hematopoietic stem cell and solid-organ transplantation, and the histocompatibility

138 epts for antibody reduction before and after solid organ transplantation are considered, to better un

139 Hematopoietic cell transplantation and solid organ transplantation are definitive therapies for

140 ions for use of the latter in the setting of solid organ transplantation are presented in the accompa

141 ial harms of routine exercise training after solid organ transplantation are unclear.

142 re remains one of the most challenging among solid organ transplantation as a result of the high rate

143 Partial T cell depletion is used in solid organ transplantation as a valuable strategy of pe

144 tients with coccidioidomycosis who underwent solid organ transplantation at our center to identify fa

145 s with previous coccidioidomycosis underwent solid organ transplantation at our institution.

146 trials, including those for bone marrow and solid organ transplantation, autoimmune diseases, and ti

147 hematopoietic stem cell transplantation, or solid organ transplantation be screened for active or pr

148 tween Jan 1, 1970, and Dec 31, 1986 (without solid organ transplantation before cohort entry) to the

149 A total of 3489 patients underwent solid organ transplantation between 1990 and 2008.

150 published with subject headings relating to solid organ transplantation between August 1, 2011, and

151 Autoimmune responses to vimentin occur after solid organ transplantation, but their pathogenic effect

152 Excessive weight (EW) gain is common after solid organ transplantation, but there is little informa

153 In the setting of solid-organ transplantation, calcineurin inhibitor (CNI)

154 Women with a history of solid-organ transplantation can be safely offered a wide

155 skin cancer, the most common neoplasia after solid organ transplantation, causes serious morbidity an

156 reviewed for randomized controlled trials in solid organ transplantation comparing an mTOR-I with a n

157 for treatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug re

158 Outcomes after solid organ transplantation continue to improve, but pre

159 The shortage of deceased donor organs for solid organ transplantation continues to be an ongoing d

160 However, the number of patients awaiting solid organ transplantation continues to remain much hig

161 ients undergoing immunosuppression following solid organ transplantation, contributing substantially

162 Solid organ transplantation creates the ideal medium whe

163 Solid organ transplantation disrupts virus-host relation

164 In solid organ transplantation, donor-derived immune cells

165 with PTLD or chronic high viral loads after solid organ transplantation exhibited no homogeneous EBV

166 9 (COVID-19) pandemic to continue lifesaving solid organ transplantation for heart, lung, liver, and

167 ressed recrudescent coccidioidomycosis after solid organ transplantation for the large majority of pa

168 he most common infectious complication after solid organ transplantation, frequently affecting the ga

169 ven patients who were HCV negative underwent solid organ transplantation from a donor who was HCV vir

170 Solid organ transplantation from hepatitis C virus-posit

171 from unrelated donors and in the setting of solid organ transplantation from living donors, the stan

172 respect to safety for recipients undergoing solid-organ transplantation from donors with a history o

173 tic stem cell transplant cohort and excluded solid-organ transplantation from this cohort.

174 Histocompatibility testing for stem cell and solid organ transplantation has become increasingly comp

175 Transmission of T. cruzi infection by solid organ transplantation has been reported in Latin A

176 Allergy transfer upon solid organ transplantation has been reported in the lit

177 Although short-term allograft survival after solid organ transplantation has improved during the past

178 Development of amyloidosis post solid-organ transplantation has not been reported, altho

179 nostic biomarkers of acute rejection (AR) in solid organ transplantation have been addressed in multi

180 or and mechanisms of colorectal carcinoma in solid organ transplantation have not been well character

181 Current immunosuppression regimens for solid-organ transplantation have shown disappointing eff

182 eing placed on a waiting list or receiving a solid organ transplantation, hazard ratios (HRs) for ide

183 As with solid organ transplantation, however, rejection must be

184 is used clinically for immunosuppression in solid organ transplantation; however, it is difficult to

185 maglobulinemia (HGG) frequently occurs after solid organ transplantation; however, the prevalence and

186 y present an opportunity for cost savings in solid organ transplantation if equivalent clinical outco

187 After solid organ transplantation, immune-mediated rejection m

188 es on cytomegalovirus (CMV) management after solid organ transplantation in 2010, which provide recom

189 was investigated during the first year after solid organ transplantation in 263 patients who received

190 for over 30 years to pay for deceased donor solid organ transplantation in America.

191 of the oral cavity, which may develop after solid organ transplantation in children.

192 d in the National Institutes of Health (NIH) Solid Organ Transplantation in HIV Trial, reflecting exp

193 liver transplant candidates enrolled in the Solid Organ Transplantation in HIV: Multi-Site Study (HI

194 es that have resulted in good outcomes after solid organ transplantation in the HIV-positive recipien

195 gional impact of coronavirus disease 2019 on solid organ transplantation in the United States has not

196 isk of recurrent or de-novo malignancy after solid-organ transplantation in HIV patients is low.

197 based cohort study of patients who underwent solid-organ transplantation in Ontario, Canada, between

198 fic exposures were associated with increased solid organ transplantation incidence.

199 Studies in other solid-organ transplantations indicate that low levels of

200 rnerstone of immunosuppressive therapy after solid organ transplantation, inhibits calcineurin activa

201 Solid organ transplantation is a curative therapy for hu

202 Solid organ transplantation is a lifesaving therapy for

203 m secondary to infectious aortitis following solid organ transplantation is a rare event that in the

204 Solid organ transplantation is a vital therapy for end s

205 Tobacco use after solid organ transplantation is associated with allograft

206 Acute kidney injury after nonrenal solid organ transplantation is associated with prolonged

207 can persist after HC graft rejection even if solid organ transplantation is delayed.

208 Solid organ transplantation is encumbered by an increasi

209 Medication nonadherence (MNA) after solid organ transplantation is highly prevalent and asso

210 However, using ID as a contraindication to solid organ transplantation is not evidence-based and re

211 Solid organ transplantation is the preferred treatment f

212 Solid organ transplantation is uncommon in ageing childh

213 The field of solid organ transplantation is unique in the breadth of

214 exercise intervention trial after pediatric solid organ transplantation is warranted to determine th

215 he use of generic immunosuppressive drugs in solid organ transplantation is warranted.

216 Cytomegalovirus (CMV) infection in solid-organ transplantation is associated with increased

217 health concern; however, the incidence post solid-organ transplantation is not well reported.

218 H1N1 swine influenza could be transmitted by solid organ transplantation led to the publication of gu

219 Severe B-lineage PTLD after solid organ transplantation may be classified as SR or H

220 KIR haplotype B from viral replication after solid organ transplantation may extend beyond CMV to oth

221 n face the highest waiting list mortality in solid-organ transplantation medicine.

222 ert Meeting of the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Consortium took plac

223 s in ameliorating common complications after solid organ transplantation must be balanced with potent

224 ole in chronic kidney disease after nonrenal solid organ transplantation (NRSOT), although there are

225 In the first meta-analysis, CMV events after solid organ transplantation occurred significantly more

226 Solid organ transplantation offers hope for long-term su

227 tly extrapolated to settings more typical of solid organ transplantation or autoimmunity.

228 promising strategy to induce tolerance after solid-organ transplantation or prevent graft-versus-host

229 OR, 3.12), radiation therapy (OR, 5.28), and solid organ transplantation (OR, 2.48) increased the ris

230 ty, are now being translated to the field of solid organ transplantation, particularly for livers and

231 mains an important opportunistic pathogen in solid organ transplantation, particularly in lung transp

232 ngly used off-label as an induction agent in solid organ transplantation, particularly in the setting

233 virus (CMV) remains an important pathogen in solid organ transplantation, particularly lung transplan

234 ing the risk of graft-versus-host disease in solid organ transplantation patients given hematopoietic

235 This study focused on the 107 adult solid organ transplantation patients who were diagnosed

236 and serum samples obtained from nonselected solid-organ transplantation patients suffering from prob

237 a, may support exclusion of pulmonary IFI in solid-organ transplantation patients, the low positive p

238 information provided through study in other solid-organ transplantation populations than our specifi

239 In solid organ transplantation recipients, exercise is able

240 udies have reported EBV(-) PTLD in pediatric solid-organ transplantation recipients.

241 Solid organ transplantation reduces both morbidity and m

242 Successful solid organ transplantation reflects meticulous attentio

243 nor-specific antibodies, conclusions made in solid organ transplantation regarding antibody-mediated

244 antigen-1 (LFA-1) blockade to inhibit BM and solid organ transplantation rejection in nonhuman primat

245 elated chain A (MICA) genes are important in solid organ transplantation rejection.

246 to support self-management, but evidence in solid organ transplantation remains unclear.

247 omplication after hematopoietic stem cell or solid organ transplantation resulting from outgrowth of

248 ains one of the most common infections after solid organ transplantation, resulting in significant mo

249 o be one of the most common infections after solid-organ transplantation, resulting in significant mo

250 The use of calcineurin inhibitors in solid organ transplantation results in an increased risk

251 oing evaluation in autoimmune and allogeneic solid organ transplantation settings, data supporting th

252 In most solid organ transplantation settings, the role of NK cel

253 Survival outcomes showed that solid organ transplantation should be considered for 5-y

254 eatures and outcomes among a large cohort of solid organ transplantation (SOT) -related patients with

255 l characteristics, and outcomes of SAB after solid organ transplantation (SOT) and compare these feat

256 ls effectively excluding patients with prior solid organ transplantation (SOT) and posttransplant lym

257 xis effectively prevents CMV infection after solid organ transplantation (SOT) but is associated with

258 Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a hist

259 e infection (CDI) treatment; however, use in solid organ transplantation (SOT) patients has theoretic

260 Information on solid organ transplantation (SOT) performed in pediatric

261 Immune measurements that distinguish solid organ transplantation (SOT) recipients who control

262 late severe infection (LI) beyond month 6 in solid organ transplantation (SOT) recipients.

263 sequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and

264 rol of cytomegalovirus (CMV) infection after solid organ transplantation (SOT) requires a functional

265 dity and mortality among patients undergoing solid organ transplantation (SOT).

266 of the net state of immunosuppression after solid organ transplantation (SOT).

267 aematopoieitc cell transplantation (HCT) and solid organ transplantation (SOT).

268 iasm as an innovative cell-based approach in solid organ transplantation (SOT).

269 receptors, in regulating the alloresponse to solid organ transplantation (SOT).

270 infection is an ongoing clinical problem in solid-organ transplantation (SOT).

271 Incidences may vary among solid organ transplantations (SOTs) and may take to part

272 t represent life-threatening complication of solid-organ transplantation (SOTx).

273 but also as a result of better therapies in solid organ transplantation, stem cell transplantation,

274 Organ scarcity continues in solid organ transplantation, such that the availability

275 gical and infectious challenges accompanying solid organ transplantation, susceptibility to post-tran

276 emphasizing the parallels between women and solid organ transplantation that could allow vaccines to

277 rfusion injury is an inherent consequence of solid organ transplantation that increases tissue inflam

278 d without hematologic malignancy or previous solid organ transplantation) that were collected for rou

279 In solid organ transplantation, the achievement of an immun

280 s, which are similar to those reported after solid organ transplantation, the patient is satisfied of

281 ) have been implicated in graft rejection in solid organ transplantation, their role in hematopoietic

282 In the setting of solid organ transplantation, there is accumulating evide

283 lusters of rabies virus transmission through solid organ transplantation, there was a long incubation

284 A consensus conference on frailty in solid organ transplantation took place on February 11, 2

285 When compared with solid organ transplantation, VCA donation and allocation

286 5-year overall survival after solid organ transplantation was 93.5% (95% CI 81.0-97.9)

287 evention and Management of CMV Disease after Solid Organ Transplantation was published in March 2011.

288 The SMR for cancer death after solid-organ transplantation was higher in children (SMR,

289 Solid-organ transplantation was identified using the nat

290 The relevance of this pathway to solid-organ transplantation was then confirmed by the de

291 Unlike solid organ transplantation, which is potentially life-s

292 investigation of how innate immunity impacts solid organ transplantation will likely lead to improved

293 Many children who have undergone solid organ transplantation will require additional supp

294 clinical research on stem cells, tissues, or solid organ transplantation with >=20 participants, whic

295 rent developments in tolerance induction for solid organ transplantation with a particular emphasis o

296 oviders, offering ideas to improve safety in solid organ transplantation with limited health care res

297 Seventy-four cases of PTLD after solid organ transplantation with sufficient material for

298 ars suggests that amyloidosis may occur post solid-organ transplantation with an overall poor surviva

299 ophic virus (HTLV)-1 has been reported after solid-organ transplantation, with a related fatal outcom

300 cipients, showing potential applications for solid organ transplantation without immune suppression.